Fenwick & West represented BioAge Labs, Inc. in the offering, and Cooley represented the underwriters. BioAge Labs, Inc. (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Elegen in the transaction. Elegen announced it raised $35 million in Series B Financing Round led by Triatomic Capital and was joined...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Attovia Therapeutics in the transaction. Attovia Therapeutics (“Attovia”), a developer of a pipeline of biotherapeutics with an initial focus on immune-mediated diseases,...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented BioAge Labs in the transaction. BioAge Labs (BioAge) announced it completed the oversubscribed $170M Series D financing round led by Sofinnova Investments...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Eychonis, Inc. in the transaction. Eyconis, Inc. announced their formation and $150 million capital raise. Eyconis was formed and launched by Ascendis...
You must be a Standard 1 Year member to access this content.
Fenwick & West LLP represented DICE Therapeutics, Inc. in the transaction, while Kirkland & Ellis represented Eli Lilly and Company. Eli Lilly and Company (NYSE: LLY)...
You must be a Standard 1 Year member to access this content.
Fenwick represented Abdera Therapeutics on the deal. Abdera Therapeutics, a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceuticals...
You must be a Standard 1 Year member to access this content.
Fenwick represented Perceive Bio on the deal. Perceive Bio, a biotech company pioneering novel technologies and therapeutics in ophthalmology, announced its $78 million Series B financing. The...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Novo Holdings and Metagenomi on the deal. Fenwick represented Metagenomi. Gene editing company Metagenomi announced a $100 million Series B...
You must be a Standard 1 Year member to access this content.
Fenwick represented Cleerly on the deal. Cleerly, a company creating a new standard of care for heart disease, announced its $192 million Series C financing. This new...
You must be a Standard 1 Year member to access this content.
Fenwick advised Melinta Therapeutics on the deal. Melinta Therapeutics, a company providing innovative therapies for acute and life-threatening illnesses, announced its acquisition of the U.S. rights to...
You must be a Standard 1 Year member to access this content.
Fenwick represented Endpoint Health on the deal. Endpoint Health, Inc., a precision-first™ therapeutics company dedicated to addressing urgent needs in immune-driven critical and chronic illnesses, announced a...
You must be a Standard 1 Year member to access this content.
